What is the problem you're trying to solve?
Cortexyme is working on a new approach to stopping the progression of Alzheimer’s disease. We have identified a pathogen in Alzheimers brain that we believe is upstream of neurodegeneration, beta amyloid and other pathology. We have a small molecule therapeutic in hand that we are rapidly advancing towards the human testing.
How is what you're doing different than other attempts to solve this problem?
Current treatments for Alzheimer’s only address the symptoms. Many other companies are working towards a cure for Alzheimer’s but most of this work has focused on a single target, beta amyloid. Unfortunately, targeting beta amyloid alone has not demonstrated efficacy in clinical studies.
Why are you passionate about what you're working on?
Like many people, I have experienced Alzheimer’s disease in my own family so I know how important it is for patients and their families to cure this disease. I’m also very passionate about the emerging science that we get to be a part of. Researchers around the world are discovering signs of inflammation and immune dysfunction in Alzheimer’s disease so it’s very exciting to see the puzzle beginning to come together and be able to contribute to that.
What achievement are you most proud of?
This is my third start-up so I’m excited and grateful for that. I hope you will ask me again in 3 years when we have data demonstrating efficacy of ourtreatment in Alzheimer’s patients. That will certainly be the greatest achievement for our entire team at Cortexyme.